Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent. ADCw, Ktrans, Ve, and Vp parameter maps were computed and co-registered across scan dates. Over 10 subjects there was an average of 44% decrease in mean tumor Ktrans 2-3 days after initiation of therapy relative to baseline Ktrans values. The decrease in whole-tumor Ktrans was significantly greater in subjects who received 24 mg/m2 drug relative to those who received 13 mg/m2 Crolibulin. Voxel-wise analysis of changes in ADCw, Ktrans, Ve, and Vp will be presented.